A. OVERVIEW The Administrative Core will coordinate and integrate facilifies, faculty, resources, and projects. The objectives of the Administrative Core include the following: 1. Oversee optimal use of Partnership funds and personnel resources; 2. Coordinate and integrate the Center Cores and component activities;and 3. Provide leadership and administrative support to the Partnership components, projects, and investigators. As demonstrated in Figure 2, Dr. Vadgama will be the Administrative Core Director and will oversee administrative activities. The Administrative Core comprises two teams, the Execufive Management Team and the Program Leadership Team. The Executive Management Team will comprise the core director and the program manager and manage funds and resources. The Executive Management Team will work closely with and be guided by the NCI program director, the Internal Advisory and Program Steering Committees of the Planning and Evaluation Core, and institutional leadership. The Program Leadership Team, consisting of all investigators and core/program leaders, will meet quarterly to be updated and involved with other core/program activities. The leadership team will be collaborative only and will not be a decision-making committee. The Administrative Core will coordinate these meetings and all cross-program communication to make certain that all Partnership components are informed, united, and/or working collaboratively on a consistent basis.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54CA143931-04
Application #
8381216
Study Section
Special Emphasis Panel (ZCA1-SRLB-D)
Project Start
Project End
Budget Start
2012-09-01
Budget End
2013-08-31
Support Year
4
Fiscal Year
2012
Total Cost
$439,629
Indirect Cost
Name
Charles R. Drew University of Medicine & Science
Department
Type
DUNS #
785877408
City
Los Angeles
State
CA
Country
United States
Zip Code
90059
Wu, Y; Vadgama, J V (2017) Androgen Receptor as a Potential Target for Treatment of Breast Cancer. Int J Cancer Res Mol Mech 3:
La, V; Fujikawa, R; Janzen, D M et al. (2017) Birinapant sensitizes platinum-resistant carcinomas with high levels of cIAP to carboplatin therapy. NPJ Precis Oncol 1:
Wang, Piwen; Solorzano, Walter; Diaz, Tanya et al. (2017) Arctigenin inhibits prostate tumor cell growth in vitro and in vivo. Clin Nutr Exp 13:1-11
Wu, Yanyuan; Tran, Trinh; Dwabe, Sami et al. (2017) A83-01 inhibits TGF-?-induced upregulation of Wnt3 and epithelial to mesenchymal transition in HER2-overexpressing breast cancer cells. Breast Cancer Res Treat 163:449-460
Maxwell, Annette E; Young, Sandra; Moe, Emily et al. (2017) Understanding Factors that Influence Health Care Utilization Among Mixtec and Zapotec Women in a Farmworker Community in California. J Community Health :
Dong, Yunzhou; Wu, Yong; Cui, Mei-Zhen et al. (2017) Lysophosphatidic Acid Triggers Apoptosis in HeLa Cells through the Upregulation of Tumor Necrosis Factor Receptor Superfamily Member 21. Mediators Inflamm 2017:2754756
Brennen, W Nathaniel; Zhang, Baohui; Kulac, Ibrahim et al. (2017) Mesenchymal stem cell infiltration during neoplastic transformation of the human prostate. Oncotarget 8:46710-46727
Kiyohara, M H; Dillard, C; Tsui, J et al. (2017) EMP2 is a novel therapeutic target for endometrial cancer stem cells. Oncogene 36:5793-5807
Wu, Yong; Yu, Xiaoting; Yi, Xianghua et al. (2017) Aberrant Phosphorylation of SMAD4 Thr277-Mediated USP9x-SMAD4 Interaction by Free Fatty Acids Promotes Breast Cancer Metastasis. Cancer Res 77:1383-1394
McGhee, Eva; Harper, Hill; Ume, Adaku et al. (2017) Elimination of Cancer Health Disparities through the Acceleration of HPV Vaccines and Vaccinations: A Simplified Version of the President's Cancer Panel Report on HPV Vaccinations. J Vaccines Vaccin 8:

Showing the most recent 10 out of 79 publications